Aug 11, 2015
Adynxx says that their second shot at statistically significant results in a mid-stage study for their lead pain drug proved the charm. The San Francisco-based biotech didn’t post any data, but CEO Rick Orr said that the drug hit the primary endpoint without raising any red flags on the safety side.
Clearing that hurdle leaves Adynxx plotting a course into late-stage development next year, says Orr, who’s now in the process of planning a slate of relatively small studies that cut across “surgical models” for AYX1. And in the meantime, the venture-backed company says it will study how best to raise the money that will be needed to cover the big gap between Phase II and registration data.